A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
D000293:Adolescent; D000328:Adult; D002746:Chlorpromazine / Q000009:adverse effects; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D009966:Orphenadrine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010546:Perphenazine / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects*; D014268:Trifluoperazine / Q000009:adverse effects
D010276:Parasympatholytics; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D009966:Orphenadrine; D010546:Perphenazine; D006220:Haloperidol; D002746:Chlorpromazine